Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

被引：328

作者：

Knight, Steven D. ^{[1
]}

Adams, Nicholas D. ^{[1
]}

Burgess, JoeIle L. ^{[1
]}

Chaudhari, Amita M. ^{[1
]}

Darcy, Michael G. ^{[1
]}

Donatelli, Carla A. ^{[1
]}

Luengo, Juan I. ^{[1
]}

Newlander, Ken A. ^{[1
]}

Parrish, Cynthia A. ^{[1
]}

Ridgers, Lance H. ^{[1
]}

Sarpong, Martha A. ^{[1
]}

Schmidt, Stanley J. ^{[1
]}

Van Aller, Glenn S. ^{[1
]}

Carson, Jeffrey D. ^{[1
]}

Diamond, Melody A. ^{[1
]}

Elkins, Patricia A. ^{[1
]}

Gardiner, Christine M. ^{[1
]}

Garver, Eric ^{[1
]}

Gilbert, Seth A. ^{[1
]}

Gontarek, Richard R. ^{[1
]}

Jackson, Jeffrey R. ^{[1
]}

Kershner, Kevin L. ^{[1
]}

Luo, Lusong ^{[1
]}

Raha, Kaushik ^{[1
]}

Sherk, Christian S. ^{[1
]}

Sung, Chiu-Mei ^{[1
]}

Sutton, David ^{[1
]}

Tummino, Peter J. ^{[1
]}

Wegrzyn, Ronald J. ^{[1
]}

Auger, Kurt R. ^{[1
]}

Dhanak, Dashyant ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Collegeville, PA 19426 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2010年 / 1卷 / 01期

关键词：

GSK2126458; phosphoinositide 3-kinase alpha; mammalian target of rapamycin; PI3K/AKT pathway; CANCER-SPECIFIC MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASES; PIK3CA; PHOSPHORYLATION; IDENTIFICATION; P110-ALPHA; PATHWAY; CELL;

D O I：

10.1021/ml900028r

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Phosphomositide 3-kinase alpha (PI3K alpha) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3K alpha and mTOR with in vivo activity in both pharrnacodynamic and tumor growth efficacy models Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

引用

页码：39 / 43

页数：5

共 27 条

[1] ADAMS ND, 2008, Patent No. 2008144463
[2] ADAMS ND, 2008, Patent No. 2008144464
[3] [Anonymous], EORTC NCI AACR INT C
[4] PDGF-DEPENDENT TYROSINE PHOSPHORYLATION STIMULATES PRODUCTION OF NOVEL POLYPHOSPHOINOSITIDES IN INTACT-CELLS
AUGER, KR
SERUNIAN, LA
SOLTOFF, SP
LIBBY, P
CANTLEY, LC
[J]. CELL, 1989, 57 (01) : 167 - 175
[5] Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, AG
Kang, SY
Vogt, PK
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) : 1475 - 1479
[6] Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M
You, H
Levine, AJ
Mak, TW
[J]. NATURE REVIEWS CANCER, 2006, 6 (03) : 184 - 192
[7] Delano W.L., 2002, CCP4 NEWSL PROTEIN C, V4, P82
[8] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, Jeffrey A.
Luo, Ji
Cantley, Lewis C.
[J]. NATURE REVIEWS GENETICS, 2006, 7 (08) : 606 - 619
[9] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Folkes, Adrian J.
Ahmadi, Khatereh
Alderton, Wendy K.
Alix, Sonia
Baker, Stewart J.
Box, Gary
Chuckowree, Irina S.
Clarke, Paul A.
Depledge, Paul
Eccles, Suzanne A.
Friedman, Lori S.
Hayes, Angela
Hancox, Timothy C.
Kugendradas, Arumugam
Lensun, Letitia
Moore, Pauline
Olivero, Alan G.
Pang, Jodie
Patel, Sonal
Pergl-Wilson, Giles H.
Raynaud, Florence I.
Robson, Anthony
Saghir, Nahid
Salphati, Laurent
Sohal, Sukhjit
Ultsch, Mark H.
Valenti, Melanie
Wallweber, Heidi J. A.
Wan, Nan Chi
Wiesmann, Christian
Workman, Paul
Zhyvoloup, Alexander
Zvelebil, Marketa J.
Shuttleworth, Stephen J.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) : 5522 - 5532
[10] Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts
Gray, A
Olsson, H
Batty, IH
Priganica, L
Downes, CP
[J]. ANALYTICAL BIOCHEMISTRY, 2003, 313 (02) : 234 - 245

← 1 2 3 →